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MATERIALS AND METHODS

Patients and participants
We studied 10 TB patients (7 males and 3 females; mean age 54.1) and 9 healthy volunteers (controls). One of the patients had received previous anti-TB chemotherapy. Table 1 summarizes the patients' backgrounds of the TB cases; all had active pulmonary TB, and one also had tongue TB. All patients were hospitalized in the Kurume University Hospital. The presence of acid-fast bacilli in the sputum was confirmed at admission, and each patient received appropriate anti-TB chemotherapy. The healthy volunteers comprised 3 males and 6 females, mean age was 45.5 years old, with history of pulmonary disease, no abnormalities on chest radiography, and were tuberculin reaction-positive. A blood sample was collected into a heparinized tube from each of the patients before the start of anti-TB chemotherapy, and at the time when the smear for Mycobacterium tuberculosis (Mtb) became negative, the erythrocyte sedimentation rate (ESR) became normal, and the C-reactive protein (CRP) became negative. The blood of healthy subjects were collected once before the study. Informed consent was obtained from each subject, and the study was approved by the Committee of the Kurume University Hospital for Studies on Human Subjects. 
Purified protein derivative (PPD)-induced proliferation
Before treatment, the growth index of the 5 patients (case nos. 1, 7, 8, 9, and 10) was much higher than the level shown in the healthy controls (i.e., 1 to 20 in the index). However, after treatment, the index in 4 of the 5 patients decreased remarkably (Fig. 4) . The 10 patients were divided into two groups according to the pretreatment growth index: high proliferation group (case nos. 1, 7, 8, 9, and 10) and normal/low proliferation group (case nos. 2, 3, 4, 5, and 6), and clinical/laboratory test results were compared between the groups (Table 3) . Before treatment, the high proliferation group had a significantly higher ESR (p<0.01) and the Gaffky score (in the 
